Written by the Nuvirox Research Team
Key Points
- A rat study found nicotinamide riboside reduced corneal and body hypersensitivity caused by a chemotherapy drug (paclitaxel) that also produces dry-eye-like symptoms.
- This research specifically targeted chemotherapy-induced dry eye syndrome, not the far more common everyday dry eye affecting up to 30% of the general population.
- A related, ongoing preclinical program is testing whether NR can prevent dry eye, neuropathy, and hearing loss caused by platinum-based chemotherapy in a veteran population.
Short answer: encouraging results in rats with chemotherapy-induced dry eye — a specific, less common cause of the condition — with no research yet on the everyday dry eye most people experience. The distinction between "dry eye caused by chemo" and "ordinary dry eye" matters a lot here, and it's easy to lose that distinction if you only skim the headline finding.
What dry eye syndrome actually is
Dry eye syndrome (DES) affects up to 30% of the population and involves disrupted tear production or quality, often accompanied by corneal nerve changes that create a cycle of irritation: dysfunction in the nerves that supply the cornea (the eye's clear front surface) can both result from and worsen tear film disruption, since those same nerves help regulate tear production. Researchers describe painful DES as sharing features with neuropathic pain more broadly, since sustained disruption of the tear film can lead to repeated or ongoing injury to those corneal nerve fibers, triggering neurogenic inflammation that further disrupts normal tear regulation — a self-reinforcing cycle rather than a single, isolated problem. Most everyday dry eye relates to factors like screen time, aging, contact lens use, certain medications, and environmental conditions — not chemotherapy.
What the research actually tested
The specific research connecting NAD+ precursors to dry eye comes from a rat model of paclitaxel-induced dry eye — paclitaxel being a chemotherapy drug used to treat several cancers, known to cause both peripheral neuropathy and dry-eye-like corneal changes as side effects. Published research (Hamity et al., IOVS/ARVO) found that nicotinamide riboside alleviated corneal and body (somatic) hypersensitivity induced by paclitaxel in male rats — a meaningful finding specifically about chemotherapy-associated ocular surface disease. The researchers' interest in this model stemmed from the broader observation that corneal nerve damage in DES functions similarly to nerve damage in other neuropathic pain conditions, suggesting that a treatment effective for one type of nerve-related hypersensitivity might plausibly extend to corneal hypersensitivity as well — the kind of cross-condition reasoning that's common in early-stage translational research but still requires direct testing in each specific context before being assumed to hold.
Study snapshot
| Model | Rat, paclitaxel-induced corneal/somatic hypersensitivity |
| Intervention | Nicotinamide riboside (NR) |
| Finding | Reduced corneal and somatic hypersensitivity vs. untreated |
| Human trial status | None yet — related VA-funded program is preclinical, extending to cisplatin |
The broader research program behind this
This work is part of a larger VA-funded research effort investigating whether NR can prevent three separate side effects of platinum-based chemotherapy (specifically cisplatin) in veterans with cancer: peripheral neuropathy, dry-eye syndrome, and hearing loss. The same research group had previously shown NR could both prevent and reverse a related chemotherapy-induced peripheral neuropathy (from a different drug, paclitaxel) in rodents. This is a coherent, multi-symptom research program — but as of this writing, it remains in the rodent-model stage for the dry eye and hearing components specifically, with no completed human trial results.
Why this doesn't generalize to everyday dry eye
Chemotherapy-induced dry eye involves a specific type of nerve toxicity from platinum or taxane drugs — a different underlying mechanism than the dry eye caused by, say, reduced blinking during screen use, contact lens wear, aging-related tear gland changes, or autoimmune conditions like Sjögren's syndrome. A finding in one doesn't automatically apply to the other, and no research we found has tested NAD+ precursors in general, non-chemotherapy-related dry eye.
What this means depending on your situation
If you're managing dry eye as a side effect of cancer treatment, this is genuinely relevant emerging research worth discussing with your oncology team, particularly if you're a veteran who might be eligible for related research programs. If you have everyday dry eye unrelated to chemotherapy, this research doesn't yet provide evidence one way or the other, and standard approaches (artificial tears, environmental changes, and an eye care professional's guidance) remain the evidence-based starting point. For related nerve-related NAD+ research from the same broader research program, see our review of NAD+ and chemotherapy-induced neuropathy, and NAD+ and age-related hearing loss covers a third side effect being studied by related research groups.
FROM NUVIROX
Because of the caveats above, we'd encourage you to read this as general background rather than a treatment plan. If you're curious about the ingredient at the center of this research, here's what's in ours, alongside clinician-routing guidance for anything beyond everyday support:
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol + 50 mg quercetin — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg fenugreek galactomannans to support absorption
- Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
Frequently asked questions
Does NAD+ help with regular dry eye, not from chemotherapy?
There's no research testing that specific question. The available evidence is limited to chemotherapy-induced dry eye in a rat model.
Has this been tested in humans undergoing chemotherapy?
Not yet, based on current search results. The broader research program is still in the preclinical (rodent) stage for the dry-eye and hearing-loss components.
What drug caused the dry eye in the study?
Paclitaxel, a taxane chemotherapy drug. A related, ongoing program is also studying cisplatin, a platinum-based chemotherapy drug, for similar effects across multiple side effects.
Should I ask my oncologist about this before starting chemo?
If dry eye, neuropathy, or hearing changes are a concern with your specific chemotherapy regimen, that's a reasonable conversation to have with your oncology team, who can speak to your individual risk and any relevant ongoing research or trials.
Why do researchers study corneal nerves and general body pain sensitivity together?
Corneal nerves and peripheral nerves elsewhere in the body share underlying biology, and chemotherapy drugs known to cause peripheral neuropathy often affect corneal nerve function through similar mechanisms — which is part of why a single study can measure both types of hypersensitivity in the same animal model.
Is dry eye syndrome always related to nerve damage?
No — dry eye has many contributing causes beyond nerve-related ones, including tear gland dysfunction, eyelid conditions, autoimmune disease, and environmental factors, so the corneal-nerve-hypersensitivity model in this research applies most directly to the specific chemotherapy-induced context it was designed to study.
What treatments are currently recommended for everyday dry eye?
Standard approaches include artificial tears, warm compresses, environmental adjustments (like reducing screen glare or using a humidifier), and in some cases prescription eye drops — an eye care professional can help determine which combination fits your specific presentation, since dry eye has multiple possible underlying causes.
The bottom line: this is real, applicable research for a specific and serious situation — chemotherapy-related eye and nerve side effects — that shouldn't be stretched to cover the much broader, much more common experience of everyday dry eye that most readers researching this topic are probably actually dealing with.
References
- Hamity MV, et al. Nicotinamide Riboside Alleviates Corneal and Somatic Hypersensitivity Induced by Paclitaxel in Male Rats. Invest Ophthalmol Vis Sci (IOVS/ARVO).
- Nicotinamide Riboside for the Treatment of Chemotherapy-Induced Neuropathy, Dry Eye Syndrome, and Hearing Loss. VA-funded research grant, I21-RX003464-01A1.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.